Basel, Switzerland, December 2008 – Evolva SA, an international biotech company focused on the discovery and development of drugs based on genetic chemistry approaches, today announced the filing of a Clinical Trial Application (CTA) for EV-077-3201-2TBS. This is a new chemical entity that is being developed for reduction of cardiovascular morbidity and mortality in patients who are hypo-responders or resistant to Aspirin and/or Clopidogrel. It is also being developed for treatment of proteinuric kidney diseases.
EV-077-3201-2TBS is a fast and reversible inhibitor of platelet aggregation. The expected benefit over antiplatelet drugs which are currently marketed or in development is that it could overcome hypo-response / resistance to existing therapies due to its mode of action.
"We are very pleased to have submitted the CTA for EV-077-3201-2TBS," said Alexandra SantAna Sorensen, VP R&D. "This is the first time Evolva has advanced a compound to the submission of a CTA and is therefore a major milestone for the company".
Upon approval of the CTA by the German Federal Institute for Drugs and Medical Devices (BfArM), Evolva will start the first-in-man study at a Phase I Unit in Germany.
Evolva uses genetic chemistry technology platforms to replicate, on an industrial basis, the ability of nature to create molecules with exquisite “design”. Development activities focus primarily on cardiovascular and infectious disease. For more information see www.evolva.com.
Alexandra SantAna Sorensen, email@example.com
Phone: +41 61 485 20 20, Mobile: +41 79 329 41 98